不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
新型滤泡辅助性 T 细胞样 T 细胞淋巴瘤疗法：从临床前评估到临床现实
英文原题：Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality.
查看英文原题
Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
外周 T 细胞淋巴瘤（PTCL）的分类持续变化，包含多个亚型。本文聚焦 Tfh 样 PTCL；根据最新 WHO 分类，血管免疫母细胞性 T 细胞淋巴瘤（AITL）属于这一类。这些恶性肿瘤的一线治疗仍以化疗为主，但疗效并不理想。过去十年，对相关基因突变及其导致的信号和表观遗传通路失调的认识取得巨大进展，使研究者得以提出新的治疗策略。这些发现指向新的生物标志物和疗法，包括低甲基化药物（如阿扎胞苷）以及针对 Tfh 型 PTCL 中 TCR 过度激活分子的抑制剂。此外，本文还讨论代谢干预、NF-κB 和 PI3K-mTOR 通路抑制剂，以及针对恶性 Tfh 细胞表面标志物的抗体和嵌合抗原受体（CAR）等潜在新型免疫疗法，以及其他新的治疗选择。
展开英文摘要原文
The classification of peripheral T-cell lymphomas (PTCL) is constantly changing and contains multiple subtypes.
Here, we focus on Tfh-like PTCL, to which angioimmunoblastic T-cell lymphoma (AITL) belongs, according to the last WHO classification. The first-line treatment of these malignancies still relies on chemotherapy but gives very unsatisfying results for these patients. Enormous progress in the last decade in terms of understanding the implicated genetic mutations leading to signaling and epigenetic pathway deregulation in Tfh PTCL allowed the research community to propose new therapeutic approaches.
These findings point towards new biomarkers and new therapies, including hypomethylating agents, such as azacytidine, and inhibitors of the TCR-hyperactivating molecules in Tfh PTCL.
Additionally, metabolic interference, inhibitors of the NF- B and PI3K-mTOR pathways and possibly novel immunotherapies, such as antibodies and chimeric antigen receptors (CAR) directed against Tfh malignant T-cell surface markers, are discussed in this review among other new treatment options.
论文信息
- 作者
- Krug A、Tari G、Saidane A、Gaulard P、Ricci JE、Lemonnier F、Verhoeyen E
- 单位
- Université Côte d'Azur, INSERM, C3M, 06204 Nice, France.France
- 文献类型
- 综述
- 期刊
- Cancers2022 May 12
- 原文标识
- PubMed 35625998 · DOI 10.3390/cancers14102392
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →